These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36320324)

  • 1. Prime editing optimized RTT permits the correction of the c.8713C>T mutation in
    Happi Mbakam C; Rousseau J; Lu Y; Bigot A; Mamchaoui K; Mouly V; Tremblay JP
    Mol Ther Nucleic Acids; 2022 Dec; 30():272-285. PubMed ID: 36320324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of In-Frame Deletion, Homology-Directed Repair, and Prime Editing-Based Correction of Duchenne Muscular Dystrophy Mutations.
    Zhao X; Qu K; Curci B; Yang H; Bolund L; Lin L; Luo Y
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prime editing strategies to mediate exon skipping in
    Happi Mbakam C; Roustant J; Rousseau J; Yameogo P; Lu Y; Bigot A; Mamchaoui K; Mouly V; Lamothe G; Tremblay JP
    Front Med (Lausanne); 2023; 10():1128557. PubMed ID: 37305116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
    Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
    PLoS One; 2020; 15(1):e0228072. PubMed ID: 31961902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing.
    Zhang Y; Li H; Nishiyama T; McAnally JR; Sanchez-Ortiz E; Huang J; Mammen PPA; Bassel-Duby R; Olson EN
    Mol Ther Nucleic Acids; 2022 Sep; 29():525-537. PubMed ID: 36035749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
    Domenig SA; Bundschuh N; Lenardič A; Ghosh A; Kim I; Qabrati X; D'Hulst G; Bar-Nur O
    Stem Cell Reports; 2022 Feb; 17(2):321-336. PubMed ID: 34995499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
    Aslesh T; Erkut E; Yokota T
    Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
    [No Abstract]   [Full Text] [Related]  

  • 10. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9.
    Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS
    Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice.
    Karri DR; Zhang Y; Chemello F; Min YL; Huang J; Kim J; Mammen PPA; Xu L; Liu N; Bassel-Duby R; Olson EN
    Mol Ther Nucleic Acids; 2022 Jun; 28():154-167. PubMed ID: 35402069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy.
    Lim KRQ; Yoon C; Yokota T
    J Pers Med; 2018 Nov; 8(4):. PubMed ID: 30477208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
    Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
    Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System.
    Lattanzi A; Duguez S; Moiani A; Izmiryan A; Barbon E; Martin S; Mamchaoui K; Mouly V; Bernardi F; Mavilio F; Bovolenta M
    Mol Ther Nucleic Acids; 2017 Jun; 7():11-19. PubMed ID: 28624187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.
    Pini V; Mariot V; Dumonceaux J; Counsell J; O'Neill HC; Farmer S; Conti F; Muntoni F
    Sci Rep; 2022 Mar; 12(1):3756. PubMed ID: 35260651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.
    Long C; McAnally JR; Shelton JM; Mireault AA; Bassel-Duby R; Olson EN
    Science; 2014 Sep; 345(6201):1184-1188. PubMed ID: 25123483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation.
    Zhang Y; Nishiyama T; Li H; Huang J; Atmanli A; Sanchez-Ortiz E; Wang Z; Mireault AA; Mammen PPA; Bassel-Duby R; Olson EN
    Mol Ther Methods Clin Dev; 2021 Sep; 22():122-132. PubMed ID: 34485599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.